|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Merck & Co., Inc. (MRK) Overstated Mumps Vaccine Effectiveness?
6/26/2012 6:59:55 AM
Two former Merck virologists are charging in a whistleblower lawsuit that the drugmaker used improper testing techniques and falsified test data, among other things, to fraudulently overstate the effectiveness of its mumps vaccines for which the federal government has paid hundreds of millions of dollars. As a result, the former Merck employees also maintain that mumps outbreaks continue to occur. Merck obtained its original, exclusive license for a mumps vaccine in 1967 and, at the time, stated that effectiveness was 95 percent, which meant that at least 95 percent of those innoculated were considered immunized from the disease, according to the lawsuit. However, new efficacy testing began in the late 1990s as part of an effort to win licensing for a second-generation measles, mumps and rubella vaccine, or MMR-II.
|
|
|
|
|
|
|
|
|
|
|